We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Butyrate and Tributyrin have at most a minor documented interaction. No reason to take both. If you want the compound with human clinical trials behind it, that is sodium butyrate. Tributyrin's case rests on a distal-colonic-delivery claim the evidence does not support — it was rapidly cleaved in the stomach compartment of a validated gut model.
Redundant rather than harmful. Critically, the clinical trial record belongs to the SALT, not the prodrug: trials of sodium butyrate in IBS and inflammatory bowel disease are evidence about sodium butyrate. Tributyrin's entire human evidence base is 50 people across three uncontrolled studies, none placebo-controlled and none meeting an efficacy endpoint.
Same active molecule, different delivery vehicle — and the comparison does not favour the prodrug. In mice, oral sodium butyrate reached roughly 9 mM peak plasma butyrate against about 1.75 mM for tributyrin, and in human visceral fat ex vivo the two performed comparably.
What to do: No reason to take both. If you want the compound with human clinical trials behind it, that is sodium butyrate. Tributyrin's case rests on a distal-colonic-delivery claim the evidence does not support — it was rapidly cleaved in the stomach compartment of a validated gut model.
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.